Clinical Trials

Inclusion Criteria:

• A diagnosis of celiac disease by intestinal biopsy.
• Following a GFD for at least 12 consecutive months.
• Must have detectable (above the lower limit of detection) serum celiac-related antibodies.
• Must have human leukocyte antigen DQ (HLA-DQ) typing consistent with celiac disease (DQ2 and/or DQ8).
• Subjects must have had at least one of the following symptoms at least once per week during the month before screening: diarrhea, loose stools, abdominal pain, abdominal cramping, bloating, or gas.
• Body weight between 35 and 120 kg.

Exclusion Criteria:

• Current diagnosis of any severe complication of celiac disease, such as refractory celiac disease type 1 (RCD-I) or RCD-II, enteropathy-associated T-cell lymphoma (EATL), ulcerative jejunitis, or gastrointestinal (GI) perforation.
• Diagnosis of any chronic, active GI disease other than celiac disease.
• Presence of any active infection.
• Selective immunoglobulin A (IgA) deficiency, defined as having undetectable levels of IgA.
• Known or suspected exposure to coronavirus disease 2019 (COVID-19) infection in the 4 weeks before screening.
• Administration of a live vaccine within 14 days prior to randomization and the first administration of study drug -History or presence of any clinically significant disease that, in the opinion of the Investigator, may confound the subject's participation and follow-up in the clinical trial or put the subject at unnecessary risk.
• Females who are pregnant or planning to become pregnant during the study period, or who are currently breastfeeding.